Predict your next investment

applied-genomics.com

See what CB Insights has to offer

Investments

1

Portfolio Exits

1

About Applied Genomics

Applied Genomics Headquarter Location

2705 Artie Street Southwest

Huntsville, Alabama, 35805-4762,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Applied Genomics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Applied Genomics in 1 Expert Collection, including Pharma Startups.

P

Pharma Startups

5,090 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

Latest Applied Genomics News

Amgen Gift to Fund Launch of KGI Center for Training in Applied Genomics

Dec 5, 2019

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191205005061/en/ Amgen's $1 million gift to Keck Graduate Institute (KGI) will provide a strong foundation for the KGI Center for Training in Applied Genomics, paving the way for the development of executive education courses, new faculty, student scholarships, infrastructure, program management, and research. (Graphic: Business Wire) “Amgen is a world leader in human genetics, which plays an increasingly important role in the development of new medicines and holds promise for improving healthcare delivery,” said Robert A. Bradway, chairman and chief executive officer of Amgen. “We are pleased to support the KGI Center for Training in Applied Genomics as it builds the next generation of experts in genomics research. This collaboration reflects Amgen’s commitment to advancing science education at all levels, from high school through post-graduate and beyond.” Human genomics, the study of the genes and DNA found in all human cells, is rapidly reshaping the way diseases are identified in patients, studied in the laboratory, and eventually treated. Studying the entire genome requires a combination of classical genetics knowledge and bioinformatics, which is the use of computer science and biostatistics to analyze the data generated from DNA sequencing. Advances in human genomics have transformed personalized medicine from science fiction into reality. Genome sequencing is now used routinely for cancer patients to tailor therapies to the exact mutations in tumors. Whole genome sequencing is used to great success in identifying rare diseases in children who previously went undiagnosed. This data is also being used to discover the biological bases of common diseases and develop new, targeted therapies using this information. As the field of human genomics advances and expands rapidly, genomics education must also adapt. The goal of the KGI Center for Training in Applied Genomics will be to create a full-spectrum educational resource. The Center will have a dual focus: the first being the education of young scientists to become leaders in the field, and the second being to provide executive and continuing education to enable current professionals to stay at the cutting edge of a field that is constantly changing. “In recognizing the need for innovation within genomics education, the KGI Center for Training in Applied Genomics will have a wide-ranging impact on industry and students,” KGI President Sheldon Schuster said. “We are deeply grateful to be supported in this effort by Amgen, which continues to demonstrate its strong commitment to KGI and our contributions to education, research, and industry.” The $1 million gift will provide a strong foundation for the KGI Center for Training in Applied Genomics, paving the way for the development of executive education courses, new faculty, student scholarships, infrastructure, program management, and research. The KGI Center for Training in Applied Genomics will be a place for biotech leaders to learn, be inspired, and connect to one another and the industry. In December 2016, Amgen gave KGI $1.5 million to help launch two genetics degrees: the Master of Science in Human Genetics and Genetic Counseling (MSGC) and the Master of Science in Human Genetics and Genomic Data Analytics (MSGDA). The first cohorts in those two programs started in August 2018 and are set to graduate in May 2020. The MSGDA is a first-of-its-kind program, providing students with opportunities to fill the growing demand for genomic interpretation of clinical DNA sequencing data through in-depth coursework in human genetics and genomics coupled with bioinformatics and data analysis skills. KGI has a long tradition of working closely with industry partners and creating programs responsive to industry needs. Amgen is a top employer of KGI alumni, and this leading biotechnology company has sponsored numerous KGI Team Master’s Projects. About Keck Graduate Institute (KGI) Keck Graduate Institute (KGI) was founded in 1997 as the first higher education institution in the United States dedicated exclusively to education and research related to the applied life sciences. KGI offers innovative postgraduate degrees and certificates that integrate life and health sciences, business, pharmacy, engineering, and genetics, with a focus on industry projects, hands-on industry experiences, and team collaborations. A member of The Claremont Colleges, KGI employs an entrepreneurial approach and industry connections that provide pathways for students to become leaders within healthcare and the applied life sciences. To learn more about KGI, visit kgi.edu . View source version on businesswire.com: https://www.businesswire.com/news/home/20191205005061/en/ Ivan Alber

Applied Genomics Investments

1 Investments

Applied Genomics has made 1 investments. Their latest investment was in AVEO Oncology as part of their Series B on October 10, 2003.

CBI Logo

Applied Genomics Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

10/10/2003

Series B

AVEO Oncology

$42.7M

Yes

Date

10/10/2003

Round

Series B

Company

AVEO Oncology

Amount

$42.7M

New?

Yes

Co-Investors

Sources

Applied Genomics Portfolio Exits

1 Portfolio Exit

Applied Genomics has 1 portfolio exit. Their latest portfolio exit was AVEO Oncology on March 12, 2010.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

3/12/2010

IPO

Date

3/12/2010

Exit

IPO

Companies

Valuation

Acquirer

Sources

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.